Pacific Biosciences and Advanced Analytical Technologies Announce Co-Marketing Agreement
April 28 2016 - 11:46AM
Pacific Biosciences of California, Inc., (Nasdaq:PACB) and Advanced
Analytical Technologies, Inc., (AATI) today announced the companies
have signed an agreement to jointly promote their technology
solutions for long-read DNA sequencing.
The PacBio® RS II and Sequel™ Systems are based on PacBio’s
proven Single Molecule, Real-Time (SMRT®) technology and
are used to sequence small or large genomes, as well as to perform
targeted sequencing, complex population analysis, and RNA
sequencing. SMRT Sequencing provides characterization of many types
of genomic variation, including those in complex regions not
accessible with short-read or synthetic long-read sequencing
technologies. It also reveals epigenetic information. AATI’s
Fragment Analyzer™ quantifies and qualifies nucleic acid samples in
one step with accurate sizing to ~50 kilobases in length. The
method takes ~1 hour (as opposed to ~16 hours with pulse field gel
electrophoresis) and can process up to 96 samples in parallel.
“We are excited to team with Advanced Analytical. Their Fragment
Analyzer will help streamline our large-insert library workflow for
de novo assemblies, where it is important to know the size of the
libraries before and after size selection,” said Kevin Corcoran,
Senior Vice President of Market Development at PacBio. “Use of the
Fragment Analyzer for accurate sizing will significantly speed the
time it takes to make a library and improve the likelihood of
project success.”
Dr. Jonathan Hagopian, Director of Business Development at
Advanced Analytical, added: “We are proud that we have met PacBio’s
high standards for data quality and performance with our Fragment
Analyzer system. Our collaboration will accelerate discoveries
based on their powerful long-read sequencing technology.”
About Pacific BiosciencesPacific Biosciences of
California, Inc. (NASDAQ:PACB) offers sequencing systems to
help scientists resolve genetically complex problems. Based on its
novel Single Molecule, Real-Time (SMRT®) technology, Pacific
Biosciences’ products enable: de novo genome assembly to finish
genomes in order to more fully identify, annotate and decipher
genomic structures; full-length transcript analysis to improve
annotations in reference genomes, characterize alternatively
spliced isoforms in important gene families, and find novel genes;
targeted sequencing to more comprehensively characterize genetic
variations; and real-time kinetic information for epigenome
characterization. Pacific Biosciences’ technology provides high
accuracy, ultra-long reads, uniform coverage, and is the only DNA
sequencing technology that provides the ability to simultaneously
detect epigenetic changes. PacBio® sequencing systems, including
consumables and software, provide a simple, fast, end-to-end
workflow for SMRT Sequencing. More information is available
at www.pacb.com.
About AATIAdvanced Analytical Technologies,
Inc., (AATI) develops, manufactures, and markets low and
high-throughput, fully-automated nucleic acid genetic analysis
systems. AATI platforms optimize and accelerate complex genomics
workflows for basic science and commercial applications in multiple
life science industries including: genomics, molecular diagnostics,
pharmaceuticals, healthcare, biotechnology, synthetic biology,
biofuels, and agriculture. The company’s product portfolio has
instruments for parallel analysis of DNA, RNA, pharmaceutical
compounds, and proteins using capillary electrophoresis (CE) with
fluorescence or UV absorbance detection. The Fragment Analyzer™ is
AATI’s flagship platform recognized as the best-in-class
multi-channel automated fluorescence-based CE detection system for
sizing and concentration analysis of various DNA and RNA samples
including: genomic DNA, NGS libraries, CRISPR mutations, dsDNA
fragments, PCR amplicons, microsatellite SSR, RFLP, total RNA,
mRNA, small and microRNA, single-cell products, and cell-free
isolates. Advanced Analytical has facilities in Ankeny, Iowa, USA
and Heidelberg, Germany. More information is available at
www.aati-us.com.
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things,
statements relating to future uses, quality or performance of, or
benefits of using, products or technologies, the expected benefits
of the agreement between Pacific Biosciences and AATI and other
future events. You should not place undue reliance on
forward-looking statements because they involve known and unknown
risks, uncertainties, changes in circumstances and other factors
that are, in some cases, beyond Pacific Biosciences’ control and
could cause actual results to differ materially from the
information expressed or implied by forward-looking statements made
in this press release. Factors that could materially affect actual
results can be found in Pacific Biosciences’ most recent filings
with the Securities and Exchange Commission, including Pacific
Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and
include those listed under the caption “Risk Factors.”
Pacific Biosciences undertakes no obligation to revise or update
information in this press release to reflect events or
circumstances in the future, even if new information becomes
available.
Contacts
Media:
Nicole Litchfield
415.793.6468
nicole@bioscribe.com
Investors:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Apr 2023 to Apr 2024